|
|
|
|
|
|
by Vecr
1541 days ago
|
|
|
The primary endpoint of the Pfizer trial was any symptomatic disease. That means they would monitor participants for symptoms, and if they had any they would be PCR tested to make sure it was not something else. They claimed the lower end of the 95 confidence interval relative risk reduction was ~90%. You can look at the prescribing guide on the FDA's website for more details. J&J did moderate to severe disease as the primary endpoint though. |
|
|